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Protein kinase aIn the heart compartmentalisation of cAMP/protein kinase A (PKA) signalling is necessary to achieve a speciﬁc
functional outcome in response to different hormonal stimuli. Chronic exposure to catecholamines is known to
be detrimental to the heart and disrupted compartmentalisation of cAMP signalling has been associated to
heart disease. However, in most cases it remains unclear whether altered local cAMP signalling is an adaptive
response, a consequence of the disease orwhether it contributes to the pathogenetic process.We have previously
demonstrated that isoforms of PKA expressed in cardiac myocytes, PKA-I and PKA-II, localise to different
subcellular compartments and are selectively activated by spatially conﬁned pools of cAMP, resulting in
phosphorylation of distinct downstream targets. Here we investigate cAMP signalling in an in vitro model of
hypertrophy in primary adult rat ventricular myocytes. By using a real time imaging approach and targeted
reporters we ﬁnd that that sustained exposure to catecholamines can directly affect cAMP/PKA compart-
mentalisation. This appears to involve a complex mechanism including both changes in the subcellular
localisation of individual phosphodiesterase (PDE) isoforms as well as the relocalisation of PKA isoforms. As a
result, the preferential coupling of PKA subsets with different PDEs is altered resulting in a signiﬁcant difference
in the level of cAMP the kinase is exposed to, with potential impact on phosphorylation of downstream targets.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
cAMP signalling mediates the catecholamine-dependent regulation
of heart rate and contraction by modulating multiple aspects of the
excitation contraction coupling (ECC) machinery [1]. The main effector
of such regulation is protein kinase A (PKA), a tetrameric enzyme
formed by two regulatory (R) and two catalytic (C) subunits. Ventricu-
lar myocytes express two PKA isoforms, PKA-I and PKA-II, which differ
in their sensitivity to cAMP and in their subcellular localisation. On bind-
ing of β-ARs by catecholamines, adenylyl cyclases are activated toA Kinase anchoring proteins;
de; ARVM, adult rat ventricular
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pling; EPAC, exchange proteins
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logy, Anatomy and Genetics,
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nd Medicine, Rayne Building, 5
. This is an open access article undergenerate cAMP; cAMP in turn binds to the R subunits of PKA releasing
active C subunits. The active enzyme phosphorylates several proteins
involved in ECC including the L-type Ca2+ channels, the ryanodine re-
ceptor, troponin I, myosin binding protein C and phospholamban,
resulting in increased contractility and enhanced relaxation of ventricu-
larmyocytes [1]. This sequence of events is fundamental in the ability of
the heart to ﬁnely adjust its output in response to continuous oscilla-
tions in oxygen demand by peripheral tissues and to react to stress sit-
uations with the ‘ﬂight or ﬁght’ response. However, persistent
catecholamine stimulation of the heart is known to result in detrimental
effects including cardiac remodelling and cardiac hypertrophy, leading
ultimately to heart failure [2–5].
In addition to regulation of contractility, cAMP mediates multiple
other physiological functions within the cardiac myocyte, including
gene transcription, with potentially negative long term effects [6]. A
number of studies conducted over recent years support a model
where spatial and temporal regulation of cAMP signals is paramount
in maintaining normal function and where accuracy of signalling is
achieved via compartmentalisation of cAMP and of the other molecular
components of the pathways that are involved in cAMP signal propaga-
tion [7,8]. This model is based on the notion that the raise in cAMP
generated by hormonal stimulation is conﬁned to distinct subcellular
compartments, such that the cyclic nucleotide can only activate athe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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number of substrates, thus achieving the appropriate functional out-
come [9]. Critical to such compartmentalisation of signalling is the an-
choring of PKA to speciﬁc subcellular sites [7] and the ability of
phosphodiesterases (PDEs), the enzymes that degrade cAMP, to regu-
late locally the level of cAMP [10,11].
Anchoring of PKA is achieved via binding of the R subunits to A
kinase anchoring proteins (AKAPs), a large family of structurally unre-
lated proteins that have in common the ability to bind to PKA and there-
by tether the enzyme to a speciﬁc location within the cell [12], bringing
it in close proximity to a speciﬁc target. Anchoring of PKA to AKAPs is
achieved via interaction of the N-terminal dimerization/docking (D/D)
domain of the R subunit with an amphipathic helix of 14–18 residues
within the AKAP [13]. The majority of AKAPs identiﬁed to date bind se-
lectively to PKA-II [12], although dual-speciﬁc AKAPs as well as several
PKA-I speciﬁc AKAPs have been reported [14,15].
The role of PDEs in shaping local cAMP signals has long been
recognised [16]. PDEs provide the only means of hydrolysing cAMP
and can restrict the diffusion of cAMP thus preventing unspeciﬁc activa-
tion of individual PKA subsets. Multiple genes and splice variants for
generating PDE isoforms targeted to distinct intracellular structures
exist [17] and individual PDE isoforms are known to be under the con-
trol of a variety of different regulatory mechanisms. Thus, changing
the amount and activation status of PDEs associated with a speciﬁc
subcellular microdomain provides an important regulatory mechanism
for local cAMP signals.
Given the high sophistication of the system underpinning com-
partmentalised cAMP signalling it is not surprising that alterations of
its local control have been found to be associated to cardiac pathology.
For example, amutation affecting the ability of theAKAPYotiao to inter-
act with PKA leads to long QT syndrome [18] and alterations in PDE ex-
pression and activity have been found in several animalmodels of heart
disease as well as in failing human hearts [19,20]. In most cases how-
ever, it has not been possible to ﬁrmly establish whether the disrupted
compartmentalisation of cAMP signalling is involved in the pathogene-
sis of the heart condition or whether it is a sequel of cardiac tissue re-
modelling that develops as a consequence of the disease. In this
study we investigate whether sustained exposure of ventricular
myocytes to high levels of catecholamines may directly affect cAMP
compartmentalisation.
2. Material and methods
2.1. Reagents
Norepinephrine, cilostamide, rolipram, forskolin, were obtained
from Sigma-Aldrich, BAY 60-7550 was from Cayman Chem.
Phosphate-Buffered Saline (PBS), DMEM High Glucose, MEM199,
Penicilline/Streptomycine (10,000 units of penicillin (base) and
10,000 μg of streptomycin (base)/ml) and Glutamine were pur-
chased from Invitrogen.
2.2. Antibodies
Mouse α-actinin was purchased from Sigma (A7811), anti-PDE2A
(PD2A-101AP) and anti-PDE3A (PD3A-101AP) were from FabGennix.
Anti-PDE4B and anti-PDE4D were kindly provided by M Houslay. Anti-
mouse IgG (A5278), anti-rabbit IgG (A8275) and anti-goat IgG (A8919)
were from Sigma. Donkey anti-goat AlexaFluor® 488 (A11055), donkey
anti-rabbit AlexaFluor® 488 (A21206) and goat anti-mouse AlexaFluor®
564 (A11055) were fromMolecular Probes (Invitriogen).
2.3. ARVMs culture and adenoviral delivery
All animal procedures in this studywere carried out according to the
HomeOfﬁce regulations regarding experiments with animals in the UK.Male Wistar rats (200 g–250 g) were sacriﬁced by cervical dislocation.
Single cardiomyocytes were isolated as previously described [21,22].
Brieﬂy, hearts were removed, cannulated, perfused and digested with
KREBS solution containing 0.66 mg/ml collagenase type I (Worthington
BioChem) and 0.04 mg/ml protease type XIV (Sigma). Isolated cardio-
myocytes were resuspended in MEM199 medium supplemented with
5 mM creatine (Sigma), 5 mM taurine (Sigma), 2 mM carnitine
(Sigma), 1% Pen/Strep. Cells were seeded at 50,000 cells per 24mmcov-
erslips coatedwith laminin (Millipore) and incubated at 37 °C. After 2 h,
cardiomyocytes were transduced with AdV5/CMV/RI_epac or AdV5/
CMV/RII_epac (MOI 1000) for 24 h.
2.4. In-vitro hypertrophy protocol
For hypertrophy induction, ARVMs were treated with 1 μM nore-
pinephrine (NE) in serum free medium. Cells were cultured for 24 h
before imaging.
2.5. Generation of AdV5/CMV/RI_epac and AdV5/CMV/RII_epac
RI_epac and RII_epac constructs [9] were cloned into the pShuttle-
CMV vector and transferred by homologous recombination into the
pAdEasy-1 vector to generate AdV5/CMV/RI_epac and AdV5/CMV/
RII_epac using AdEasy™XLAdenoviral Vector System (Agilent Technol-
ogies— Stratagene Products), according to manufacturer's instructions.
2.6. Real-time PCR
Total RNA was extracted from cultured ARVM using TRIzol reagent
(Invitrogen) which contained phenol and guanidine thiocyanate in a
procedure based on the method of Chomczynski and Sacchi [23]. Re-
verse transcription of RNA samples was carried out using QuantiTect®
Reverse Transcription Kit (Qiagen) according to manufacturer's
instructions.
Gene-speciﬁc TaqMan probes and PCR primers sets were designed
and purchased from Euroﬁns MWG operon. Real-time PCR was per-
formed from reverse transcribed cDNA samples using the Platinum
Quantitative PCR SuperMix-UDG with ROX (Invitrogen) following the
manufacturer's instructions. qPCR reactions were conducted using the
ABI Prism 7300 (Applied Biosystems) qPCR thermocycler and analysis
software (95 °C for 2 min, followed by 40 cycles of 95 °C for 15s, 57 °C
for 15 s, 60 °C for 1 min). 18S rRNA was used as an internal control.
18S rRNA primers and TaqMan probe sequences;
Forward: 5′-CGCGGTTCTATTTTGTTGGT-3′,
Reverse: 5′-CGGTCCAAGAATTTCACCTC-3′,
TaqMan: 5′-FAM-TGAGGCCATGATTAAGAGGG-TAM-3′.
Atrial natriuretic peptide (ANP) primers and TaqMan probe
sequences;
Forward: 5′-GGATTGGAGCCCAGAGCGGAC-3′,
Reverse: 5′-CGCAAGGGCTTGGGATCTTTTGC-3′,
TaqMan: 5′-FAM-AGGCTGCAACAGCTTCCGGT-TAM-3′.
α-actin primers and TaqMan probe sequences;
Forward: 5′- TCACCAAGCAGGAGTACGAC-3′,
Reverse: 5′- AGAGAGAGCGCGTACACAGA-3′,
TaqMan: 5′-FAM-ATGCTTCTAGGCGCACCCGC-TAM-3′.
Three biological replicates each of which included a minimum of
three technical replicates were performed. The relative quantity of
each transcriptwas determined using the comparative Ctmethod by in-
terpolating the Ct values of the unknown samples to each standard
curve [24]. Values were normalised with respect to 18S gene.
2.7. Cell size measurements
Single ARVM were chosen randomly and captured in bright ﬁeld
using an ORCA AG (model C4742-80-12AG) camera on the stage of
an inverted epiﬂuorescence microscope (Olympus IX81, equipped
Fig. 1. Adult rat ventricular myocytes treatedwith norepinephine (NE) for 24 h develop hypertrophy. (A) Representative images of adult rat ventricular myocytes (ARVM) untreated and
after 24 h treatment with NE (1 μM). Scale bar is 10 μm. (B) Longitudinal section area of ARVM calculated for untreated control or NE (1 μM) treated cells. n ≥ 90. Pixel size =
0.116 × 0.116 μm. (C) mRNA levels for ANP andα-actin in NE (1 μM) treated ARVM. Ribosomal 18 s subunit mRNAwas used as control. n ≥ 7. Data expressed asmean± SEM. Two tailed
paired t-test performed for panel B. One way ANOVA with Dunnett's post-test performed for panel C.
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analysed. Cell size was determined by calculating the sectional
area as length of the cell by width of the cell. One pixel corresponds
to 0.116 × 0.116 μm.
2.8. FRET imaging
FRET imaging experiments were performed 24 h after ARVMs trans-
duction with the AdV5/CMV/RI_epac or AdV5/CMV/RII_epac virus. Dur-
ing imaging cells were maintained at room temperature in a modiﬁed
Ringer solution (NaCl 125 mM, KCl 5 mM, Na3PO4 1 mM, MgSO4
1mM,Hepes 20mM, Glucose 5.5mM, CaCl2 1mM, pH 7.4), and imaged
on an inverted microscope (Olympus IX81) using a PlanApoN, 60X, NA
1.42 oil immersion objective, 0.17/FN 26.5 (Olympus, UK).
The microscope was equipped with an ORCA-AG CCD camera
(C4772-80- 12AG, Hamamatsu Photonics, UK) and a beam-splitter opti-
cal device (Dual-view simultaneous imaging system, DV2 mag
biosystem, Photometrics, ET-04-EM). FRET ﬁlter settings used were:
CFP excitation ﬁlter ET436/20×, dichroic mirror 455DCLP (Chroma
Technology) in the microscope ﬁlter cube; dichroic mirror 505DCLP,
YFP emission ﬁlter 545 nm, CFP emission ﬁlter 480 nm (Chroma Tech-
nology) in the beam splitter. Images were acquired using CELLΛ R soft-
ware (Olympus) and processed using ImageJ. FRET changes were
measured as changes in the background-subtracted 480/545 nm ﬂuo-
rescence emission intensity on excitation at 430 nm and expressed as
either R/R0, where R is the ratio at time t and R0 is the ratio at time =
0 s, or ΔR/R0, where ΔR = R–R0. Values are expressed as the mean ±
SEM.
2.9. Phosphodiesterase activity assay
Measurement of PDE activity was carried out using a radioactive cy-
clic AMPhydrolysis assay as previously described [25] and is amodiﬁca-
tion of a two-step procedure [26].
ARVMwere homogenised in lysis Buffer (50mMKCl, 50mMHepes,
1.94 mM MgCl2, 10 mM EGTA, 1 nM DTT) and protein concentration
quantiﬁed by Bradford assay. 20–25 μg of puriﬁed protein was used
per sample. Samples were assayed in a reaction mixture containing
40 mM Tris–HCl (pH 8.0), 1 mM MgCl2, 1.4 mM β-mercaptoethanol,
2 μM cAMP and 3 μCi/ml of 8-[3 H]cAMP for 10 min at 30 °C. The reac-
tion was terminated by heat inactivation in a boiling water bath for
2 min. The PDE reaction product 5′-AMP was then hydrolysed by with
50 μg of Crotalus atrox snake venom for 10 min at 30 °C, and then sepa-
rated by anion exchange chromatography using a Dowex/ethanol mix.
Samples were quantiﬁed by scintillation counting. Individual PDE activ-
ities were deﬁned as the fraction of cAMP-PDE activity inhibited by
50 nM Bay 60–7550, 10 μM cilostamide, and 10 μM rolipram. DMSO
and non-selective PDE inhibitor IBMX (10 μM) were used as controls.
Speciﬁc PDE activity was determined as pmol cAMP hydrolysed/min/
mg protein.2.10. Immunostaining and confocal imaging
ARVM were transduced with adenovirus carrying RI_epac or
RII_epac as described above and cultured for 24 h. For PDE localisation
experiments, non-transduced myocytes were used. Cells were ﬁxed
with ice cold methanol, permeabilised in PBS containing 0.1% Triton®-
X-100 and incubated for 30 min with blocking buffer (PBS containing
1% BSA). Primary antibodies were diluted in blocking buffer and incu-
bated overnight at 4 °C. For each coverslip treated with primary anti-
body, an IgG control was prepared.
Confocal images were acquired using a 63× Zeiss oil immersion
objective on a Zeiss Pascal LSM510 laser-scanning confocal microscope
(Carl Zeiss). An argon laser was used to excite AlexaFluor® 488-
conjugated donkey anti-rabbit IgG or Alexa Fluor® 488-conjugated
donkey anti-goat IgG secondary antibodies. Helium/neon lasers were
used to excite goat anti-mouse AlexaFluor® 568. Zeiss Pascal software
was used to collect images. Pearson's correlation coefﬁcient was calcu-
lated using ImageJ software with JACoP plugin.
2.11. Statistical analysis
Data are expressed as mean ± SEM. Differences between multiple
groups were compared by analysis of variance (ANOVA) followed by
multiple comparisons post-test, as indicated. Two-group analysis was
performed by t-test. Number of replicates is indicated in the ﬁgure leg-
ends. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ns = not signiﬁcant.
3. Results
To assess whether compartmentalised cAMP signalling may be
altered by sustained exposure to catecholamines we treated adult rat
ventricular myocytes (ARVM) with 1 μM norepinephrine (NE) for
24 h, a well-established protocol to induce cardiac myocyte hypertro-
phy in vitro [27–29]. As expected, after treatment the cells displayed in-
creased size (Fig. 1A, B) and reactivation of the foetal gene programme,
as illustrated by increased mRNA levels for atrial natriuretic peptide
(ANP) and skeletal α-actin (Fig. 1C), conﬁrming that this protocol in-
duces amodiﬁcation of the cellular phenotype that recapitulates a num-
ber of changes observed in hypertrophic hearts in vivo [30].
3.1. Hypertrophic cardiac myocytes show altered distribution of PKA-I and
PKA-II binding sites
To assess whether sustained exposure to catecholamines may have
an effect on the localisation of PKA isoforms we used the RI_epac and
RII_epac FRET-based cAMP sensors [9]. As illustrated in Fig. 2A these
sensors include the D/D domain from PKA-I and PKA-II, respectively,
fused at the amino-terminus of the Epac1-camps cAMP FRET reporter
[31]. The presence of the isoform-speciﬁc D/D domain confers to the
Fig. 2. Localisation of RI_epac and RII_epac reporters. (A) Schematic representation of the FRET reporters RI_epac and RII_epac. The dimerisation/docking domains from PKA-RIα and PKA-
RIIβ, which mediates anchoring of the sensors to speciﬁc AKAPs, are shown in white and black, respectively. (B) Left panels: confocal images illustrating the localisation of RI_epac or
RII_epac (in green) and the reference marker sarcomeric α-actinin (in red) in ARVM expressing the sensor in culture for 24 h without any further treatment. Right panels: line intensity
proﬁles for RI_epac and RII_epac (in green) andα-sarcomeric actinin (in red). The position of the linewhere the intensity values were calculated is shown in the correspondingmagniﬁed
panels on the left. (C) Samples are as in A except that cells were treated for 24 hwith NE (1 μM). (D) Pearson's correlation coefﬁcient calculated for RI_epac or RII_epac and sarcomericα-
actinin in untreated and NE-treated ARVM. n ≥ 7. Data expressed as mean ± SEM. Two-way ANOVA with Bonferroni multiple comparisons tests was performed. Scale bars are 10 μm.
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PKA-I and PKA-II normally bind within cardiac myocytes [9,21].
ARVM expressing RI_epac or RII_epac and immuno-labelled with
an antibody to α-actinin, a protein localised at the sarcomeric Z
line, were analysed by confocal microscopy. The speciﬁc localisation
of the sensors was assessed by estimating the degree of their relo-
cation relative to α-actinin by calculating Pearson's correlation coef-
ﬁcient (PCC) values. As shown in Fig. 2B and 2C, RI_epac and RII_epac
show a clearly distinct localisation in untreated cells (PCC values of0.79 ± 0.03 for RI_epac, n = 15, and 0.60 ± 0.02 for RII_epac, n =
13, p = 0.0001). Sustained treatment with NE signiﬁcantly altered
the localisation of both sensors as evident from the ﬂuorescence in-
tensity line scan analysis (Fig. 2C) and as conﬁrmed by PCC values
(Fig. 2D; p = 0.0003 and p = 0.0426 for RI_epac and RII_epac, re-
spectively). The relocalisation of PKA-I and PKA-II sites in hypertro-
phic cells completely abolished the difference between the two
sensors present in untreated cells (RI_epac: 0.63 ± 0.03, 9; RII_epac:
0.69 ± 0.02, n = 9, p = 0.34).
Fig. 3. Effect on local cAMP signals of sustained exposure of ARVM to catecholamines. Representative kinetics of cAMP changes detected in the PKA-I and PKA-II domains in response to ISO
(100nM), IBMX(10 μM)and forskolin (25 μM) inRI_epac orRII_epac expressing (A) untreatedARVMor (B) ARVMtreated for 24hwithNE (1 μM) to inducehypertrophy.At the end of the
experiment 25 μM forskolin was applied to achieve saturation of the sensor. Ratio values are calculated as R/R0. (C) Summary of data measured as shown in A) and B) and expressed as
increment of FRET signal over basal. n ≥ 15. Data are mean ± SEM. Two-way ANOVA with Tukey's multiple comparisons tests were performed.
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hypertrophic cardiac myocytes
To assess whether sustained exposure to catecholamines may affect
the level of cAMP that is sensed by individual PKA isoforms in response
to β-AR stimulation, we performed FRET-based imaging of ARVM ex-
pressing RI_epac or RII_epac. Untreated cells were challenged with iso-
proterenol (ISO, 100 nM) and the amplitude of FRET change was
monitored in the PKA-RI and PKA-RII subcellular compartments. The
sensor targeted to the PKA-II compartment detected a signiﬁcantly larg-
er increase in cAMP as compared to the sensor targeted to the PKA-RI
compartment (ΔR/R0 = 4.13 ± 0.22%, n = 26 for RI_epac and ΔR/
R0 = 6.20 ± 0.22%, n = 31 for RII_epac: p b 0.0001) (Fig. 3A, C).
When, in the presence of ISO, the PDEs where inhibited with the non-
selective inhibitor IBMX, a larger FRET change was detected in the
PKA-I compartment as compared to the PKA-II compartment resulting
in abrogation of the differences in cAMP levels in the two compartments
(RI_epac ΔR/R0 = 9.38 ± 0.31%, n = 26; RII_epac ΔR/R0 = 10.11 ±
0.25%, n = 27; p = 0.403) (Fig. 2A, C). These data indicate that in
non-hypertrophic cells ISO stimulation generates a compartmentalised
cAMP response that depends on a greater PDEs activity associatedwith the PKA-RI compartment compared to the PKA-RII. In striking
contrast, the cAMP response to ISO in hypertrophied cells was largely
blunted compared to controls and identical in the two compartments
(Fig. 3B, C) (ΔR/R0 = 2.137 ± 0.215% for RI_epac, n = 28 and ΔR/
R0 = 1.774 ± 0.146% for RII_epac, n = 34; p = 0.9501). Non-
selective PDE inhibition in hypertrophic myocytes resulted in a compa-
rable FRET change in the two compartments (ΔR/R0 = 7.162± 0.316%
for RI_epac, n= 26;ΔR/R0= 8.023 ± 0.301% for RII_epac, n= 15, p=
0.4139). These results together indicate that sustained exposure to cat-
echolamines results in largely reduced cAMP levels in response toβ-ARs
stimulation, an effect that is particularly prominent in the PKA-II do-
main, and the compartmentalisation of the cAMP signal is abolished.
3.3. Sustained exposure to catecholamines does not affect the overall
activity of individual PDEs
The above data indicate that sustained treatment of ARVMwith cat-
echolamines affects compartmentalisation of cAMP signals in the PKA-I
and PKA-II domains. Thismay be due to the observed relocation of PKA-I
and PKA-II induced by the treatment, resulting in coupling of the PKA
isoforms with a different array of local PDEs. However, a change in the
Fig. 4. Overall PDE activity in untreated and hypertrophic myocytes. PDE activity was
measured by radio-enzymatic assay using 2 μM cAMP as substrate. Cell lysates from
untreated and NE-hypertrophied ARVM were assessed in the presence of PDE inhibitors
Bay 60–7550 (50 nM), cilostamide (10 μM), rolipram (10 μM) or IBMX (10 μM). n ≥ 5.
Data represent mean ± SEM. Two-way ANOVA with Bonferroni post-tests were
performed.
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zyme expression, or an effect on the local regulation of individual PDEs
could also be a contributing factor. To assess whether sustained expo-
sure to catecholamines affects the overall activity of PDEs, a PDE activity
assayswas performed on cell lysates of hypertrophic and control ARVM.
Lysates were treated with PDE inhibitors and the amount of cAMP hy-
drolysis was calculated. As expected, non-selective PDE inhibition
with IBMX resulted in a large decrease in cAMP hydrolysing activity
(Fig. 5). Application of selective PDE inhibitors showed decreasing over-
all hydrolysing activity for PDE4, PDE3 and PDE2 (Fig. 4). However, no
difference was detected between untreated and hypertrophic myocytes
for all inhibitors (Fig. 4).
3.4. Hypertrophic myocytes show altered local PDE activity
To assess whether any speciﬁc PDEs may be primarily responsible
for the altered compartmentalisation observed, untreated or NE-
hypertrophied ARVM expressing either RI_epac or RII_epac were pre-
incubated with a selective PDE inhibitor before challenge with 100 nM
ISO. As shown in Fig. 5A selective inhibition of PDE2 with Bay 60 7550
(50 nM) increased the rise in cAMP in the PKA-I and PKA-II compart-
ments in both untreated and hypertrophic cells. Selective inhibition of
PDE3 with cilostamide (10 μM) resulted in a cAMP increase exclusively
in the PKA-I domain of untreated cells whereas it appeared to have no
detectable effect in hypertrophic myocytes (Fig. 5B). Pre-treatment of
control ARVM with the PDE4 selective inhibitor rolipram (10 μM)Fig. 5. Contribution of individual PDEs to the local regulation of cAMP. FRET measurements of
expressing either RI_epac or RII_epac and pre-incubated for 10minwith (A) Bay 60–7550 (50 n
as mean ± SEM. Two-way ANOVA with Tukey's multiple comparisons tests were performed.showed an effect in both domains (Fig. 5C) whereas in hypertrophic
myocytes the effect of PDE4 inhibition was detectable exclusively in
the PKA-II compartment (Fig. 5C). These ﬁndings suggest that sustained
exposure to catecholamines results in loss of PDE3 and PDE4 activity in
the PKA-RI compartment and enhanced PDE4 activity in the PKA-RII
compartment in the hypertrophic ARVM.
To assess whether sustained exposure to catecholamine may affect
the localisation of individual PDEs we performed immunoﬂuorescence
and confocal microscopy analysis of untreated and NE-treated ARVM
decorated with anti-PDE (PDE2A, PDE3A, PDE4B or PDE4D) and anti-
α-actinin antibodies and calculated the corresponding PCC values. As
shown in Fig. 6, our analysis shows no difference between control and
hypertrophic cells in the localisation for PDE2 and PDE3. Interestingly,
the localisation of PDE4B and PDE4D appeared to be altered in hypertro-
phic myocytes where a higher correlation coefﬁcient between PDE and
α-actininwas detected, suggesting that sustained exposure to catechol-
aminemay result in relocalisation of PDE4 isoforms to the Z line (Fig. 6F,
PDE4B control cells: 0.44 ± 0.03, n = 20; PDE4B hypertrophic cells:
0.60 ± 0.03, n = 12, p = 0.0006; Fig. 6H, PDE4D control cells: 0.54 ±
0.02, n = 12; PDE4D hypertrophic cells: 0.65 ± 0.04, n = 7, p = 003).
4. Discussion
Enhanced activity of the sympathetic nervous system and the in-
creased release of NE from the sympathetic nerve endings within the
myocardium has long been recognised to be associated with a number
of pathophysiological conditions leading to cardiac hypertrophy and
heart failure [32]. In this studyweused a simpliﬁed in vitromodel of car-
diacmyocyte hypertrophy to explorewhether sustained exposure toNE
directly affects the activity of PDEs and/or the localisation of PKA iso-
forms with effects on compartmentalised cAMP signalling. For our
ivestigation we used targeted cAMP sensors that allow monitoring of
the cAMP level at subcellular sites were PKA-I and PKA-II are localised
within ARVMs. We found that, in agreement with previous data ge-
nerated in neonatal rat ventricular myocytes [9], in ARVM the two
PKA isoforms are exposed to signiﬁcantly different levels of cAMP in re-
sponse to ISO stimulation and that PKA-II is the isoform that is exposed
to the strongest cAMP signal. This conﬁrms a high degree of compart-
mentalisation of cAMP in cardiacmyocytes and the preferential engage-
ment of PKA-II isoforms dowstream of β-AR activation, indicating that
this isoform is the main effector of the cAMP-dependent regulation of
ECC. In striking constrast, sustained exposure of ARVM to NE results in
a dramatic reduction in the cAMP response to ISO and the difference
in cAMP levels between the PKA-I and PKA-II domains is abolished.
This appeares to be the consequence of two mechanisms: i) relo-
calisation of PKA and ii) a change in the coupling of the relocalised
PKA isoforms with PDEs. The fact that the reduction in the strength of
the cAMP signal predominantly affects the PKA-II domain is particularly
relevant as this isoforms requires a higher concetration of cAMP to be
activated compared to the PKA-I isoform [33]. Thus, it appears that
sustained exposure to catecholamines abrogates the possibility tocAMP levels generated in response to ISO (100 nM) by untreated and NE-treated ARVMs
M), n ≥ 7; (B) cilostamide (10 μM), n ≥ 8; or (C) rolipram (10 μM), n ≥ 7. Data are expressed
Fig. 6. Localisation of individual PDE families in normal and hypertrophic myocytes. Confocal images of untreated (upper row) and NE-treated (lower row) ARVMs immunostained with
anti-α-actinin (red) and (in green) antibodies to PDE2A (A), PDE3A (C), PDE4B (E) and PDE4D (G). The corresponding PCC's are shown in panels B, D, F and H, respectively. Images were
acquired at the confocal microscope. Data expressed as mean ± SEM. Two tailed; unpaired t-tests were performed. For all experiments n ≥ 3.
731L.A. Fields et al. / Cellular Signalling 28 (2016) 725–732differentially activate the two PKA isoforms and that particularly the ac-
tivation of PKA-II is compromised, with potential impact on the regula-
tion of ECC.
Several studies have shown altered expression and/or activity of
PDEs in cardiac hypertrophy and heart failure in a number of animal
models as well as in human failing hearts. In general the data reported
so far indicate a decreased activity of PDE3 and PDE4 [19,34] andincreased activity of PDE2 [22,35,36], although the exact PDE makeup
of cardiac myocytes appears to vary depending on the stage of the dis-
ease [20]. Given the complexity of the in vivo processes leading to cardi-
ac remodelling and heart failure, published studies have not been able
to establish whether the alterd activity of PDEs observed is simply a by-
stander effect of the pathological remodelling, whether it represents an
adaptive process or whether it contributes to the development of the
732 L.A. Fields et al. / Cellular Signalling 28 (2016) 725–732disease (but see [22]). Our analysis suggests that the reduced cAMP re-
sponse observed upon sustained exposure to catecholamines is due not
only to the expected downregulation ofβ-ARs [37], but it is also the con-
sequence of a redistribution of the PKA enzyme that brings PKA-II under
a tighter control by PDEs. Indeed, we show a relocation of PDE4B and
PDE4D enzymes to sites where also PKA-II appears to relocalise. Inter-
estingly, relocalisation of PKA isoforms has been reported in human fail-
ing hearts [38].
In summary, our results indicate that sustained β-AR stimulation
signiﬁcantly affects cAMP compartmentalisation, it leads to redistri-
bution of PKA isoforms and it abrogates the potential to differentially ac-
tivate them. This may result in substantially reduced activation of PKA,
and particularly of PKA-II, with potential consequences on the regula-
tion of myocyte contractility. Our present ﬁndings suggest that the
relocalisation of PKA isoforms and disruption of PDE-dependent
compartmentalisation of cAMP signallingmay be an early event in con-
ditions of sustained adrenergic drive. The observed changes may signif-
icantly contribute to the reduced adrenergic reserve of the heart and
therefore contribute to the pathogenetic process.
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